#JPM21: Avidity CSO Art Levin runs full speed to the clinic with 'dream' antibody oligonucleotide conjugate therapy

Art Levin is living his “scientist’s dream come true.”

The Avidity Biosciences CSO set out years ago to build a new class of oligonucleotide-based therapies for severe muscle diseases, like myotonic dystrophy (DM1) — the rare, genetic disorder that causes progressive muscle weakness.